Drugs Made In America Acquisition II Corp. (DMII) Financial Statements

1 Followers

Drugs Made In America Acquisition II Corp. Financial Overview

Drugs Made In America Acquisition II Corp.'s market cap is currently $655.09M. The company's EPS TTM is $; its P/E ratio is -145.41; Drugs Made In America Acquisition II Corp. is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 24
Income Statement
Total Revenue	$ 0.00
Gross Profit	$ 0.00
Operating Income	$ -151.72K
EBITDA	$ -151.72K
Net Income	$ -151.72K
Balance Sheet
Cash & Short-Term Investments	$ 17.04K
Total Assets	$ 138.06K
Total Debt	$ 250.10K
Net Debt	$ 233.06K
Total Liabilities	$ 254.78K
Stockholders' Equity	$ -116.72K
Cash Flow
Free Cash Flow	$ -194.30K
Operating Cash Flow	$ -194.30K
Investing Cash Flow	$ 0.00
Financing Cash Flow	$ 211.33K

Currency in USD

Drugs Made In America Acquisition II Corp. Earnings and Revenue History

Income Statement >

Drugs Made In America Acquisition II Corp. Debt to Assets

Balance Sheet >

Drugs Made In America Acquisition II Corp. Cash Flow

Cash Flow >

Drugs Made In America Acquisition II Corp. Forecast EPS vs Actual EPS

Currently, no data available

Please return soon. This page is being updated.

Earnings >